Evaluation of Anti-Mullerian Hormone, Follicular Stimulating Hormone, Antral Follicle Count and ovarian volume as a different predictor for ovarian response in cases of polycystic ovary syndrome | ||||
| Al-Azhar International Medical Journal | ||||
| Volume 2023, Issue 1, January 2023 | ||||
| DOI: 10.58675/2682-339X.2135 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Mohammed Hanafy Mustafa Saad1; Yehia AbdEl Salam Wafa2; Ismael El Garhy2; Mekky Abd EL Monem3 | ||||
| 1Obstetrics and Gynecology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt | ||||
| 2Professor of Obstetrics and Gynecology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt | ||||
| 3Professor of Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. | ||||
| Abstract | ||||
| Background: Anti-mullerian hormone, also referred to as AMH, is a glycoprotein that belongs to the transforming growth factor-B family of proteins. Recent research has suggested that anti-mullerian hormone may be a useful indicator of ovarian follicular development. Its reliability super passes that of inhibin B, Estradiol & Follicular Stimulating Hormone (FSH). It demonstrates 4 biochemical parameters for follicular state that are not shared by the traditional hormone predictors. Aim of the work: Primary goal of this research is to examine the connection that exists among different parameters (Anti-mullerian hormone, Follicular Stimulating Hormone, antral follicle count (AFC) and size of the ovaries) in persons with polycystic ovary syndrome & the response of these patients to ovulation induction. Patients & methods: This prospective trial was executed in Infertility Clinics at Al-Azhar University Hospitals and El Fayoum General Hospitals. This study includes fifty (50) patients diagnosed to have polycystic ovary syndrome in accordance to Rotterdam criteria 2003. These criteria contained the following: Clinical hyperandrogenism (hirsutism using modified Ferriman-Gallwey Score more than and equal 8) or biochemical hyperandrogenism (either higher total testoterone greater than 2.1 nmol/L or free testosterone above 0.03 pmol/L); oligomenorrhea (fewer than 6-9 menses per year) or oligo-ovulation; polycystic ovaries on ultrasound (≥12 antral follicles in each ovary measuring 2-9 mm in diameter, and/or ovarian volume equal 10 cm3 or more). Results: We found that cases with elevated anti-mullerian hormone levels responded less favorably to ovulation induction than those with low anti-mullerian hormone levels. Ovarian size, FSH and age all had positive associations. Ovarian response and hormonal status in those with PCOS can be predicted by anti-mullerian hormone. Conclusion: Ovulation induction outcomes in females with PCOS may be predicted by measuring serum AMH concentrations before treatment, which could make ovulation-induction procedures more individualized as well as economical. | ||||
| Keywords | ||||
| Follicular Hormone; Mullerian Hormone; Ovary syndrome | ||||
|
Statistics Article View: 15 |
||||
